[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Omicron, half of common colds", "description": "Half of people in the UK with a common cold have a covid cold\nCheck out Wefwafwa's channel for more about our community health work in Uganda, https://www.youtube.com/c/WefwafwaAndrew\n\nONS, 13th December 2021 to 19th  December 2021\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/24december2021\n\nEngland\n\nPercentage of people testing positive for coronavirus (COVID-19), 2.83%\n\n1,544,600 people in England had COVID-19\n\nOne in 35 people\n\nLondon 1 in 20 people had COVID-19\n\nWales, One in 45\n\nNorthern Ireland, one in 40\n\nScotland, one 65 people\n\nSA data\n\nhttps://www.worldometers.info/coronavirus/country/south-africa/\n\nSA hospital data\n\nhttps://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/daily-hospital-surveillance-datcov-report/\n\nUK data\n\nhttps://coronavirus.data.gov.uk\n\nhttps://www.gov.uk/government/publications/covid-19-omicron-daily-overview\n\nTim Spector\n\nhttps://www.youtube.com/watch?v=CIGC310hPoI&t=142s\n\nOmicron, similar cold type symptoms to delta in the first few days\n\nOmicron cases have less anosmia\n\nFever is less common\n\nHaving 5 or more symptoms less common with omicron than delta\n\nMore breakthrough infections with delta, after 2 or 3 doses of vaccine\n\nCommon colds less transmissible than omicron just now\n\nOne in two chance common cold symptoms will test positive for covid\n\nTherefore, test for colds\n\nAvoid people who have a cold\n\nPings are now too slow to be effective\n\nOmicron onset, 2 days rather than 5 for delta\n\nOmicron will run its course faster, all over in 4 or 5 days\n\nInfection risk after 8 days in negligible\n\nIOM, back to work when symptoms resolve and 2 lateral flow tests\n\nFrom 17,000 omicron cases\n\nhttps://covid.joinzoe.com/post/the-20-symptoms-of-covid-19-to-watch-out-for\n\nhttps://covid.joinzoe.com/post/everything-we-know-so-far-about-omicron\n\nhttps://joinzoe.com/learn/category/covid\n\nhttps://joinzoe.com/learn/new-omicron-variant\n\nRunny nose\n\nHeadache\n\nFatigue (either mild or severe)\n\nSneezing\n\nSore throat\n\n(NHS test and trace is not telling users of their Omicron status anymore)", "link": "https://www.youtube.com/watch?v=wBQWNbJG1q8", "date_published": "2021-12-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Positive UK data", "description": "Less people going to hospital with Omicron infection compared to Delta infection. Apologies, I had a few technical problems with todays video\n\nZoe update: Wednesday 22 December 2021\n\nhttps://www.youtube.com/watch?v=CIGC310hPoI\n\nhttps://covid.joinzoe.com/post/everything-we-know-so-far-about-omicron\n\nhttps://joinzoe.com/learn/category/covid\n\nhttps://joinzoe.com/learn/new-omicron-variant\n\n144,284 new daily symptomatic cases of COVID in the UK\n\nIn people who have had at least 2 vaccine doses\n\n56,346 new daily symptomatic cases in the UK\n\n70% + cases in England are now Omicron \n\nThe UK R value, 1.2\n\nR value in London is 1.5.\n\nFrom 17,000 omicron cases\n\nRunny nose\n\nHeadache\n\nFatigue (either mild or severe)\n\nSneezing\n\nSore throat\n\n(NHS test and trace is not telling users of their Omicron status anymore)\n\nReport 50 - Hospitalisation risk for Omicron cases in England\n\nhttps://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron/\n\nhttps://www.theguardian.com/world/2021/dec/22/risk-of-hospital-stay-40-lower-with-omicron-than-delta-uk-data-suggests\n\nDifferences in the risk of hospitalisation between Omicron and Delta\n\n1st to 14th December inclusive\n\nAnalysed data from all PCR-confirmed SARS-CoV-2 cases in England\n\nCases\n\nS-gene Target Failure (SGTF) and genetic data\n\nOmicron, n = 56,000\n\nDelta, n = 269,000\n\nReduction in the risk of hospitalisation for Omicron relative to Delta infections \n\nEndpoint, any attendance at hospital\n\n20-25% reduced risk\n\nEndpoint, hospitalisation lasting 1 day or longer\n\n40-45% reduced risk\n\nThese reductions must be balanced against the larger risk of infection with Omicron, \ndue to the reduction in protection provided by both vaccination and natural infection. \n\nIntrinsic differences in severity between Omicron and Delta\n\nOmicron may result in slightly less severe disease\n\nFrom the few neither previously infected nor vaccinated, \n\nrisk of hospitalisation, 11% lower for Omicron versus Delta\n\nLevel of protection from previous infection\n\nReduces the risk of any hospitalisation by 50% \n\nReduces the risk of a hospital stay of 1+ days by 61%\n\nRisk of symptomatic infection with omicron\n\nMore protection after PF/MD than AZ \n\nHospitalisation risk by vaccination state\n\nAstraZenca (AZ) (doses 1 and 2)\n\nOmicron hazard ratios are lower than for Delta\n\nPfizer or Moderna (PF/MD) (doses 1 and 2)\n\nOmicron hazard ratios are similar to those seen for Delta\n\nConclusions, after at least 2 vaccine doses\n\nProtection against omicron infection has been largely lost\n\nRemain substantially protected against hospitalisation\n\nDoes not substantially change Sage modelling\n\nPointing to 3,000 daily hospitalisations in England at the peak next month\n\n\n\nOmicron cases in Scotland, Eave II study\n\n(Early Pandemic Evaluation and Enhanced Surveillance of COVID-19) \n\nhttps://www.sciencemediacentre.org/data-from-scotland-on-omicron-severity-from-the-eave-ii-study/\nhttps://www.ed.ac.uk/usher/eave-ii/key-outputs/our-publications/severity-of-omicron-variant-of-concern-and-vaccine\nhttps://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-\n\nHospital data from 23 November to 19 December\n\nRisk of hospitalisation, 70% lower with Omicron than Delta.\n\n15 hospitalisations with Omicron\n\nOpposed to the 47 admissions from delta\n\n(Expected given the characteristics of those infected)\n\nFirst case of Omicron confirmed by viral sequencing was recorded in Scotland on November 23, 2021\n\nBy December 19, 2021, there were 23,840 S gene negative cases. \n\nThese S gene negative cases were predominantly in the age group 20-39 (11,732; 49.2%). \n\nReinfections, more than 10 times more likely with omicron\n\nOmicron positive cases that were reinfections, 7.6%\n\nDelta cases that were \nreinfections, 0.7%\n\nThe third/booster vaccine dose was associated with a 57% reduction in the risk of symptomatic omicron infection\n\n(relative to \u226525 weeks post second dose)\n\n\nInterpretation \n\nThese early national data suggest that Omicron is associated with a two-thirds reduction in the risk of COVID-19 hospitalisation when compared to Delta. \n\nWhilst offering the greatest protection against Delta, the third/booster dose of vaccination offers substantial additional protection against the risk of symptomatic COVID-19 for Omicron,\n\nwhen compared to \u226525 weeks post second vaccine dose.", "link": "https://www.youtube.com/watch?v=4qzKh_S4Qs0", "date_published": "2021-12-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]